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Abstract
Background: In Canada, targeted vaccination of at risk groups for hepatitis A (HA) is done since
the mid 1990s resulting in declining incidence. This study estimated the year and age specific
hospitalization rates and distribution of risk factors for HA in Quebec, Canada, between 1990 and
2003.
Methods: Records of patients hospitalized with HA-related diagnostic codes were retrieved from
the provincial database. Hospital charts of all deceased cases and a random sample of all other
records were reviewed.
Results: From 1503 hospitalization records, 573 charts were reviewed including 49 (91%) of the
54 deceased patients. Confirmed acute HA was present in 79% of records where HA was the
primary diagnosis, and in 3%–8% of records where HA was a secondary diagnosis. From the total
estimated number of hospitalizations, 96% had HA as the primary diagnosis. The hospitalization
rate decreased from 1.06 per 100 000 person-years between 1990 and 1997 to 0.36 between 1998
and 2003. During the study period, 54% HA hospitalizations were in 20–39 year-olds. The overall
case fatality ratio among hospitalized patients was 1.4%, increasing from 0.4% in those < 40 years
old to 12.5% in those ≥60 years. By decreasing order, reported risk factors were travel to HA
endemic countries (30%), MSM (18%) and household contacts (11%).
Conclusion: HA hospitalization rates have been low since 1998 but the cause of this is unclear
given the cyclical pattern of HA. Travel to endemic countries remains the most important risk
factor and improved control of HA will require better strategies to vaccinate travelers.
Background
The epidemiology of hepatitis A (HA) varies according to
geographical, environmental and socio-economic condi-
tions [1-3]. The reported incidence of HA in Canada
remained above 4 per 100 000 between 1980 and 1997
and decreased thereafter (Figure 1) [4]. Hepatitis A exhib-
ited a cyclical pattern with peaks in 1984, 1991 and 1996.
Quebec, Canada's second largest province (7.2 million
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people) reported a much lower incidence before 1990 and
no peak in 1984. Since 1990, incidence has been more
similar to that of the country and displayed a synchrony
regarding the peak years (Figure 1). These peak years
occurred when two large outbreaks affected men who
have sex with men (MSM) in Montreal [5,6]. After these
outbreaks, the incidence declined substantially. It is hard
to know if this was attributable to a larger use of the vac-
cine of if it is part of the normal HA cyclical pattern.
Since its licensure in 1994, HA vaccine has been offered to
travelers going to HA endemic countries. However, only a
small fraction consult and receive HA vaccination for
which they have to pay[7,8]. Apart from the intervention
targeting MSM in 1996–1997 during which 15000 doses
of hepatitis A vaccine were administered free of charge to
approximately 8500 individuals, there has been no fur-
ther mass campaign [6]. Since 1998 in Quebec, individu-
als belonging to other high risk groups as defined by the
National Advisory committee on Immunization (NACI)
are eligible to be vaccinated free of charge [9,10]. In addi-
tion to hemophiliacs, people with chronic liver disease
and household contacts of an acute case of HA, high risk
groups also include MSM, illicit drug users and street
youths, three groups difficult to identify and reach. While
a few thousand doses are distributed annually by the
regional public health units, there is currently no data
regarding the overall vaccine coverage.
While there is good data on reported incidence of HA in
Canada, data on hospitalization remain scarce and of
uncertain validity. One study estimated hospital admis-
sions through the Hospital Morbidity Databases from the
Canadian Institute for Health Information (CIHI). It
found that the age-adjusted hospitalization rate for hepa-
titis A decreased from 2.5 to 0.6 per 100000 persons
between 1984–1998 [4]. However, only primary or prin-
cipal diagnoses were analyzed and no validation was done
of the diagnoses even if it is known that coding errors are
present in such administrative databases [11,12]. A review
of a sample of medical charts is necessary to confirm the
diagnosis and obtain valid data.
In this study, we reviewed a sample of medical charts of
patients recorded in an administrative database as having
been hospitalized with a diagnosis of HA between 1990
and 2003 in the province of Quebec, Canada, to validate
the accuracy of the diagnosis. We then estimated the age-
specific rates of hospitalization and risk factors for hospi-
talized HA cases in that population.
Methods
Source of data
MED-ECHO (Maintenance et exploitation des données
pour l'étude de la clientèle hospitalière) is a computerized
administrative database which includes data on all admis-
sions to one of the 136 acute care hospitals in the prov-
ince. Long term care facilities are not included. A record is
generated for each admission and data extracted from the
hospitalization summary sheet completed by the treating
physician after the patient is discharged. For each hospi-
talization, a primary, and up to 15 secondary diagnoses
are entered, using the ninth revision of the International
Classification of Diseases (ICD9). The primary diagnosis
indicates the disease that lead to the admission or the
complication that contributed most to the duration of the
hospitalization whereas secondary diagnoses indicate
underlying conditions that may or may not have contrib-
uted to the hospitalization.
Study population
The study population included all hospitalizations
between April 1st, 1990 and March 31st, 2003 for which
HA was recorded at any diagnostic position. HA was iden-
tified using ICD-9 diagnostic codes 070.0 (hepatitis A
with coma) and 070.1 (hepatitis A without coma).
Records were excluded if the patient was not a resident of
Quebec. During the study period, there was a total of
1503 records of hospitalization with HA, including 54
deaths (Table 1). HA was the primary diagnosis in 883
and one of the secondary diagnoses in 610 records.
Medical chart review
All 54 deaths cases and a random sample of 545 other
records stratified for the position of HA diagnosis were
selected for medical chart review. The random sample
included 25% (225/883) of records with HA as the pri-
mary diagnosis and 56% (320/569) in any other position
(Table 1). In the latter group, the sample included 67%
(110/163) of cases with HA diagnosis in the 1st secondary
position, 52% (60/116) in the 2nd secondary, 72% (60/
83) in the 3rd secondary and 44% (90/204) cases with HA
in the 4th to 15th secondary positions. The sample size was
calculated to provide a precision of estimates varying from
± 8% to ± 10%, assuming that the proportion of con-
firmed HA was 75% for diagnosis in the primary position
and 20% in each secondary position.
After study participation approval by hospital's directors
of professional services, archivists were provided a
denominalized list of hospitalization records to be
retrieved. For individual record identification, the age,
gender, admission date, and diagnoses were provided to
archivists by the research team. Denominalized photo-
copies of the medical charts for the specific hospitaliza-
tion and for follow-up visits when related to HA were
transmitted to the investigators. Demographic data, pres-
ence of risk factor for HA, clinical and laboratory informa-
tion were extracted from the charts by study nurses on a
standardized form.BMC Infectious Diseases 2007, 7:31 http://www.biomedcentral.com/1471-2334/7/31
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Confirmed acute HA cases
Acute HA cases were laboratory confirmed if patients had
a positive IgM anti-HAV serology. Clinically confirmed
acute cases were patients who did not have serological
testing but had clinical signs and symptoms compatible
with HA and traveled to a HA endemic country in the 60
days prior to onset of symptoms or had an epidemiologi-
cal link with a laboratory confirmed HA case. Hospitaliza-
tion was considered not attributable to HA if the chart
clearly indicated that hospitalization was due to another
disease even if HA was laboratory confirmed. Past HA
cases were patients with a history of prior HA or with IgG
anti-HAV testing positive but negative to or without IgM
serology.
For deaths, two physicians reviewed separately the medi-
cal charts to determine if it was attributable to HA. Death
was clearly attributable to hepatitis A if HA caused all or
the majority of the events leading to death. Death was
considered possibly attributable to HA if patients died
from concurrent complications of severe underlying con-
ditions and the role of HA was not prominent. Hepatitis
A was not contributing to the death when a clearly defined
etiology other than HA was the cause of the death. In the
case of disagreement between physicians, they met and a
consensus was reached.
Statistical analysis
The total number of hospitalizations attributable to HA
was estimated for each diagnostic position multiplying
the proportion of confirmed acute HA causing the hospi-
talization in the random sample by the total number of
records in that position plus the confirmed acute HA
deceased cases. To estimate age-specific rates, this calcula-
tion was done for each age group and the result was
divided by the adjusted 1996 census data used as the
denominator. For the three months of 2003, rates were
annualized. As two large outbreaks in the MSM commu-
nity occurred in 1991 and 1995–97, the period between
1990 to 1997 was named the "outbreak period" and that
between 1998 and 2003 was the "non-outbreak period".
The proportion of hospitalized cases was calculated by
dividing the estimated number of hospitalized cases by
the number of cases reported to the Provincial Notifiable
Reported Incidence per 100 000 Between 1980 and 2003 in Quebec and Canada Figure 1
Reported Incidence per 100 000 Between 1980 and 2003 in Quebec and Canada.
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Disease Database. The case-fatality rate among hospital-
ized patients was calculated by dividing the number of
deaths attributable to HA by the estimated total number
of hospitalizations for HA. Exact binomial statistics were
used to calculate 95% confidence intervals (CI). Propor-
tions were compared using the two-sided Mantel-Haen-
szel χ2 test or Fisher's exact test. The Wilcoxon test was
used to compare non-parametrical distribution like age.
Trends were evaluated with Mantel-Haenszel χ2 test for
trend. P value ≤ 0.05 was considered significant.
The study protocol was approved by Quebec University
Hospital Center's Research Ethics Committee.
Results
Of the 54 requested medical charts of deceased patients,
49 (91%) were obtained, whereas in the random sample,
524 (96%) of the 545 requested charts were received
(Table 1). The most frequent reason for not getting a chart
was the impossibility for hospital archivists to identify a
patient by lack of computerized data at the beginning of
the study period in some hospitals. The median age was
similar in patients whose charts were reviewed and the
other patients (P = 0.55) when the diagnosis was in pri-
mary position but it was 4 years younger when the diag-
nosis was in any secondary position (P = 0.002).
The chart review of the 49 deceased patients found that
only 11 (22%) had a confirmed acute HA at the time of
hospitalization. The proportion of confirmed acute cases
was 67% (9/12) when HA was the primary diagnosis in
contrast to 5% when HA was a secondary diagnosis (Table
1). Amongst these 11 confirmed acute cases, one died
from an apparently unrelated pneumonia whereas death
was attributable to hepatitis A virus for the other 10 (7
clearly, 3 possibly) cases. The age distribution of these 10
cases was 2 patients < 40 years old, 4 aged 40–59 years
and 4 who were ≥60 years. Three had no underlying med-
ical conditions, three had a chronic hepatitis B, one had
alcoholic cirrhosis and 3 had a cardio-vascular disease.
In the random sample, the review of the 524 medical
charts showed that 324 (62%) patients did not have acute
HA, 182 (35%) were hospitalized for confirmed acute HA
(157 (86%) were laboratory confirmed) and 18 (3%) had
acute HA that did not cause the hospitalization. Of the 26
(14%) HA cases without serology testing, 16(62%)
occurred before 1994 and only 1 (3%) had no testing in
1999–2003. Among patients with no acute HA, 158
(49%) had a history or a serologic evidence of past HA,
131 (40%) had an acute hepatitis of another etiology, and
35 (11%) had no hepatitis at all (Table 1). Among the 182
confirmed cases, 7 (4%) had a chronic liver disease. No
liver graft was reported in any of the reviewed charts.
In charts where HA was the primary diagnosis, 79% were
confirmed acute cases. This proportion was 82% for the
patients <60 years and 42% for those 60 years and older
Table 1: Validation of recorded HA diagnosis in hospitalized cases, Quebec, 1990–2003
Primary Diagnosis 1st secondary 2nd to 15th secondary¶ Total
A – DEATHS
Deaths 13 3 38 54
Charts received 12 (92%) 2 (67%) 35(92%) 49 (91%)
After chart review
Confirmed acute HA * 9 (75%) 0 (0) 2 (6%) 11 (22%)
Deaths related to HA * 8 (67%) 0 (0%) 2 (6%) 10 (20%)
B – RANDOM SAMPLE
Records in MED-ECHO 880 160 409 1449
Records sampled (sampling %) 225 (26%) 110 (67%) 210 (51%) 545 (38%)
Charts received (% of requested records) 216 (96%) 103 (94%) 205 (98%) 524 (96%)
After chart review
1)Confirmed acute HA
caused hospitalization* 170 (79%) 8 (8%) 4 (3%) 182 (35%)
did not cause hospitalization* 1 (0.5%) 6 (6%) 11 (5%) 18 (3%)
2) No acute HA* 45 (21%) 89 (86%) 190 (93%) 324 (62%)
Prior HA 5 43 110 158
Infectious hepatitis but not A 21 17 23 61
Non-infectious hepatitis 19 21 30 70
No hepatitis 0 7 24 31
Error in data entry 0 1 3 4
Estimated number of hospitalizations attributable to HA† 699 13 8 730
* % of confirmed acute cases calculated amongst the number of charts received
† Adjusted for the proportion of acute cases in 3 age groups: ≤39 years, 40–59 years, and ≥60 years.
¶ Presented in a single category as there was no difference between the different positions of diagnosis.BMC Infectious Diseases 2007, 7:31 http://www.biomedcentral.com/1471-2334/7/31
Page 5 of 7
(page number not for citation purposes)
(P = 0.003). Overall, the proportion of confirmed acute
HA cases was 8% for a diagnosis in 1st secondary and 3%
for other secondary diagnosis (Table 1) with no statisti-
cally significant difference between age groups for these
positions (P ≥ 0.08). The total estimated number of hos-
pitalizations attributable to HA during the study period
was 730 and 96% of them had HA as the primary diagno-
sis. As 522 (72%) cases were <40 years of age, 176 (24%)
were 40–59 years and 32 (4%) were ≥60 years old, the
estimated case-fatality rate among hospitalized patients
was 1.4% (CI 95% 0.66%–2.50%), increasing from 0.4%
before 40 years of age (CI 95%, 0.05%–1.37%), to 2.3%
(CI 95%, 0.62%–5.70%) for those between 40 and 59
years, and to 12.5% (CI, 3.5%–29.0%) for those ≥60 years
of age.
Adjusting the number of hospitalizations reported in
MED-ECHO with the percentage of confirmed acute cases
found in the chart review, the mean hospitalization rate
for the study period was estimated at 0.77 per 100000 per-
sons, decreasing from 1.06 per 100000 persons during the
outbreak period to 0.36 in the non-outbreak period (Fig-
ure 2). For the study period, the hospitalization rate was
0.7, 1.15, 0.68 and 0.21 per 100000 among persons aged
less than 20 years, 20–39 years, 40–59 years and 60 years
and older respectively. The mean hospitalization rate per
100 000 for the outbreak and non-outbreak period was
0.86 and 0.53 respectively for the patients aged less than
20 years, 1.68 and 0.35 for the 20–39 years old, 0.97 and
0.34 for the 40–59 years old and 0.27 and 0.09 for the 60
years and older. Overall, the median length of stay for HA
was 4 days: it increased from 3 days for patients aged less
than 20 years to 4, 5 and 7.5 days for those aged 20–39,
40–59 and 60 years and older respectively (χ2 for trend, P
= 0.05). Overall, 19% of hospitalizations occurred in
those less than 20 years, 54% in 20–39 year-olds, 23% in
40–59 year-olds, and 4% in 60 years and older (p <
0.001). For the entire study period, 19% of cases reported
to the Provincial Notifiable Disease Database were hospi-
talized. It was 21% in patients aged less than 20 years,
17% for those 20–39 years, 23% for those 40–59 years
and 16% for patients 60 years and older (P = 0.7).
Epidemiological risk factors for acquisition of HA were
present in the medical charts of 119 (65%) of the 182 con-
firmed acute cases. By order of declining importance, non-
mutually exclusive risk factors were: travel to endemic
countries (30%), MSM (18%), household contact of a
case (10%), IDU (6%) and others (homeless, institution-
alized patient, patient with chronic liver disease) (5%).
MSM represented 22% of hospitalized cases in the out-
break period and 5% in the non-outbreak period whereas
travel to a HA endemic country was almost unchanged
during the two periods (30% vs 33%).
Discussion and conclusion
Administrative hospitalization databases can be helpful
in identifying patients hospitalized for a specific condi-
tion and are used to evaluate the epidemiology, the bur-
den of the disease, and the impact of a vaccination
program [12-15]. As diagnoses recorded in MED-ECHO
are written by the treating physician on the hospital sepa-
ration sheet, the results of this study are likely to apply to
similar administrative databases relying on the physi-
cians' diagnoses. As 96% of the total estimated number of
hospitalized HA cases had their diagnosis in the primary
position in our study, this suggests that focusing a search
for acute cases of HA among those hospitalized with a
diagnosis in the primary position in similar administra-
tive database would not miss many cases. However, diag-
nosis must be confirmed to ensure the validity of results
as demonstrated by the review of medical charts which
found confirmation of HA in 75% of patients who died
and in 79% of other patients. Thus, non validated esti-
mates as those calculated for Canada using only the prin-
cipal or primary diagnosis might overestimate HA
hospitalization rates by 20% to 25% [4]. Thus the overall
hospitalization rate of 1.06 per 100 000 estimated in Que-
bec for the outbreak period (1990–1997) compared to
1.26 reported for Canada suggest that the actual rates were
similar.
However both estimates limited the case ascertainment to
records where HA was diagnosed, a strategy which may
underestimate the hospitalization rates. We did not seek
cases among patients with other diagnoses such as hepati-
tis B, other hepatitis, or liver disease. Patients whose med-
ical charts had no laboratory results and no data
concerning possible epidemiological links as undeter-
mined hepatitis, but may in fact have been HA cases. This
is unlikely to have significantly biased the results as it
occurred only in 4% of the primary diagnosis and did not
happen for any other diagnosis position. Also, given the
very low percent of confirmed acute cases in patients
where HA was recorded as a secondary diagnosis it is
expected that this proportion would be much lower in
patients where HA is not a recorded diagnosis.
Almost half of the confirmed HA cases with death
occurred in persons aged 60 years and older and our case-
fatality ratio was highest in this age group. This is consist-
ent with previous data which showed that severity of the
disease and case-fatality rates increase with age[3,16]. Our
overall proportion of incident HA cases that were hospi-
talized was 19% which is in the range of proportion
reported in the USA (11–22%)[17]. Our rates of hospital-
ization estimated for the period 1998–2003 are lower
than those from England and Wales, Belgium, Austria and
Germany (> 0.8 per 100 000) but higher than in the Neth-
erlands (≤ 0.2 per 100 000)[18]. There is no recent data onBMC Infectious Diseases 2007, 7:31 http://www.biomedcentral.com/1471-2334/7/31
Page 6 of 7
(page number not for citation purposes)
HA hospitalization rate in the USA, but combining the
number of hospitalized cases of HA from the hepatitis sur-
veillance report in 2002 [19] and data from the Bureau of
Census Estimates of the U.S Residents [20], in 2002 it can
be estimated to be in the range of 0.31 to 0.36 per 100000,
similar to our estimates.
While it is possible that risk factors differ between non-
hospitalized and hospitalized HA cases, hospitalized cases
are likely to give a good representation of risk factors exist-
ing in the population. The outbreaks in MSM in the 1990s
evidenced that they constitute a group where long lasting
transmission can occur and their vaccination remains a
priority. However, even during the MSM outbreak years,
travel to an HA endemic country was the most frequently
reported risk factor and has been present in 32% of hospi-
talized cases since 1998 (data not shown). Vaccination of
these travelers is unlikely to improve rapidly with the cur-
rent travel clinic strategy and importations of HA will
probably continue [7,8]. The cause of the lower incidence
and hospitalization rates observed in Quebec since 1998
is still unclear but is also similar to those observed in
other low endemicity countries. Given the cyclical pattern
of HA and because the vast majority of the population
remains unvaccinated, we cannot rule out a resurgence of
this disease in the next years despite some use of the vac-
cine by individuals belonging to high risk groups.
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